Rebusquillo, Fortunato P.

HRN: 23-35-17  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/12/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/12/2025
06/19/2025
IV
500mg
Q8
Indirect Inguinal Hernia Left Reducible
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Intra-abdominalProphylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: